Connective Tissue Disease Patients With Pulmonary Hypertension

Nanjing Medical University

Status

Not yet enrolling

Conditions

Connective Tissue Diseases

Pulmonary Hypertension

Treatments

Other: No Intervention

Study type

Observational

Funder types

Other

Identifiers

NCT05980728

JSPH cohort

Details and patient eligibility

About

Adult patients with suspected or confirmed Connective Tissue Disease Patients (CTD)With Pulmonary Hypertension(PH)will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and blood taken. The collection of data and biological material will mirror usual clinical practice as far as possible. Subjects will ideally attend further visits at 3, 6 and 12 months to have bloods taken, outcome measures recorded and questionnaires completed.

Enrollment

500 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Definite diagnosis of CTD included Systemic lupus erythematosus（SLE） diagnosed according to the 2019 The European Alliance of Associations for Rheumatology（EULAR） criteria, primary Sjogren's syndrome (pSS) defined according to the 2016 American College of Rheumatology(ACR) criteria, Systemic Sclerosis(SSc) defined according to the 2013 ACR criteria, mixed connective tissue disease (MCTD) defined by Sharp criteria, and Rheumatoid Arthritis(RA) defined according 2010 ACR criteria of two or more CTD at the same time were defined as having overlap syndrome (OS). Patients who had clinical and serological manifestations suggestive of systemic autoimmune diseases but did not fulfil the classification criteria for CTD were defined as having undifferentiated CTD (UCTD).
PAH was diagnosed by right heart catheterization was defined as mean Pulmonary Artery Pressure (mPAP)>20 Millimeters of mercury（mmHg）, Pulmonary Artery Wedge Pressure（PAWP）≤15mmHg, Pulmonary Vascular Resistance（PVR）>2 Wood

Exclusion criteria

significant interstitial lung disease or chronic obstructive pulmonary disease;
left heart disease or congenital heart disease associated with pulmonary hypertension;
chronic thromboembolic pulmonary hypertension;
portal hypertension;
drug or toxin exposure;
HIV infection;
any other diseases known to be associated with PAH;
age<18 years.